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httpicense.Abstract Background: Chronic obstructive pulmonary disease (COPD) is a lung disease that is
thought to result from chronic inﬂammation that may affect other organ systems. Evidence suggests
that the prevalence of osteoporosis in patients with COPD is high and potentially important. Cur-
rently, the gold standard to assess osteoporosis non-invasively is dual energy X-ray absorptiometry
(DEXA) scan.
Purpose: We wanted to investigate the prevalence of osteoporosis in a population of patients
with COPD and to determine the severity of osteoporosis in correlation with degree of COPD.
Methods: This study was conducted on 50 patients with COPD and 10 healthy subjects as a con-
trol group. Study subjects were divided into four groups Group included 10 healthy volunteers as a
control group. Group included 20 patients with moderate COPD. Group included 22 patients with
severe COPD. Group IV included 8 patients with very severe COPD. All subjects were subjected to;
detailed clinical history, thorough clinical examination, plain chest-X-ray postero-anterior view,
ventilatory function tests (spirometry), and measurement of bone density by using DEXA.
Results: The results of this study revealed signiﬁcant reduction of body mass index (BMI) in
COPD group in comparison with the control group (p value <0.05). As regards osteoporosis, its
prevalence in total COPD group was higher than control group and reached 26%, while osteopenia
reached 54%. Comparison between the COPD degrees as regards bone mineral density (BMD)
revealed that, prevalence of osteoporosis increases with the increase of the severity of COPD from
moderate to severe then very severe (20%, 27.3%, and 37.5% respectively). Highly signiﬁcant sta-1272797744 (Egypt)/+966
(M.E. Abdalla).
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92 A. Godah EL-Gazzar et al.tistical correlation was found between T score and FEV1% in COPD group revealing that osteo-
porosis severity increases with the increase of the severity of COPD.
Conclusions: Prevalence of osteoporosis was higher in COPD patients. Prevalence and severity of
osteoporosis increased with the increase of COPD degree.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Table 1 Characteristic of subjects.
Patients Control
Age
Mean ± SD 56.04 ± 7.14 49 ± 4.42
t Test 2.325
p Value 0.663 NS
BMI
Mean ± SD 23.86 ± 3.75 26.50 ± 5.40
t Test 3.625
p Value 0.049 S
This table compare between COPD patients and control as regards
age and BMI.
Table 2 Comparison between COPD groups and control
group as regards number and percentage of normal, osteopenia
and osteoporosis.
Normal Osteopenia Osteoporosis Total
Control
n 8 2 0 10
% 80 20 0
Moderate COPD
n 7 9 4 20
% 35 45 20 100
Severe COPD
n 3 13 6 22
% 13.6 59.1 27.3 100
Very severe COPD
n 0 5 3 8
% 0 62.5 37.5 100
Total of COPD
n 10 27 13 50
% 20 54 26 100
As regards BMD (represented by T score), osteopenia and osteo-
porosis frequency increases as degree of COPD passes from
moderate to very severe.Introduction
Chronic obstructive pulmonary disease (COPD) is character-
ized by a progressive airﬂow limitation that is not fully revers-
ible and associated with an abnormal inﬂammatory response
of the lung to noxious particles and gasses [1]. A variety of sys-
temic effects become obvious as the disease progress.
Osteoporosis has been recognized as one of the systemic ef-
fects of COPD and debate continues on the precise mecha-
nisms involved and on the options for treatment [2].
Osteoporosis is a systemic skeletal disease characterized by a
decreased bone mineral density (BMD) and/or deterioration
of the micro architecture, resulting in increased bone fragility
and hence an increased susceptibility to fractures [3].
The gold standard to diagnose osteoporosis is dual energy
absorptiometry (DEXA) scan. With this technique the amount
of mineral in the scanned area of bone is measured in grams and
divided by the measured bone surface in square centimeters to
acquire a deﬁnite bonemineral density (BMD). The BMD score
of patients is expressed asT score. The deﬁnition of osteoporosis
according to the WHO is based on this T-score [3].
It has been reported that BMD is lower in COPD patients
than in healthy subjects [4]. One of the most obvious causes of
osteoporosis in COPD patients is treatment with glucocorti-
coids, both as systemic therapy and as inhaled glucocorticoids
[5,6]. Glucocorticoid use does not fully account for the low
bone mineral density (BMD) and high prevalence of osteopo-
rosis in COPD patients [7].
A number of factors have been suggested to account for
these ﬁndings. COPD patients are often smokers, as well as
they have impaired mobility due to decreased muscle mass
and respiratory dysfunction. Further, the group of patients
with the most severe COPD also has lower weight than the
general population, and low BMI is further a risk factor of in-
creased mortality. All these factors are known to pre-dispose
to osteoporosis, and can explain the increased prevalence [8].
Aim of the work
The aim of this study was to determine the frequency of oste-
oporosis in COPD patients, and to determine the severity of
osteoporosis in correlation with degree of COPD.
Patients and methods
This study was conducted on 50 patients of COPD and 10
healthy subjects as a control group; they were selected from
Chest Department, Benha Faculty of Medicine from Decem-
ber 2009 to April 2010. The study protocol was approved by
the local ethics committee. Informed consent was obtained
from the patients. Age of COPD group ranged from 40 to
68 years, they were all males; while age of the control groupranged from 40 to 55 years, they were all males also. Study
subjects were divided into four groups. Group included 10
healthy volunteers who had no symptoms or signs of any chest
disease and normal ventilatory function tests as a control
group. Group included 20 patients with moderate COPD.
Group included 22 patients with severe COPD. Group IV in-
cluded 8 patients with very severe COPD. Group , and IV in-
cluded patients who had symptoms of chronic airﬂow
obstruction and who fulﬁlled lung function criteria and classi-
ﬁcation as set out by the National Heart and Lung Institute/
World Health Organization Global Initiative for Chronic
Obstructive Lung Disease guidelines [9]. Exclusion criteria in-
Table 3 Comparison between T score of COPD patients and
control group.
T score of patients T score of control
Mean ± SD 1.908 ± 0.325 0.11 ± 0.02
t Test 16.80
p Value 0.001 \ HS
As shown there is highly signiﬁcant difference in T score between
two groups.
Table 4 Linear regression analysis using least square method
between forced expiratory volume in the ﬁrst second (%
predicted) and T score.
Regression statistics of FEV1
Multiple R 0.98
R square 0.66
Adjusted R square 0.97
Standard error of the estimate 47.33
Number of cases 13 Cases
There was direct relation between FEV1% and T score.
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control moderate severe very severe
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ical diagnosis of asthma, history of childhood respiratory dis-
orders, chest wall deformity, known immunodeﬁciency.
All subjects were subjected to the following studies; full
clinical history, thorough clinical examination, plain chest X-
ray (postero-anterior and lateral views), blood sample for com-
plete blood picture, ESR, liver and kidney functions, electro-
cardiogram, Ventilatory function tests, spirometry was
performed using ‘‘Spirosift spirometry 5000 FUKUDA DEN-
SHI’’. Bone Density Measurement; for all patients and con-
trols, bone mineral density of the lumbar spines was
measured by dual energy X-ray absorptiometry (DEXA) with
the use of Norland, XR 46 apparatus. The mean BMD value
of the second, third and fourth lumbar vertebrae (lumbar spine
BMD) were used in the present young adult sex-matched con-
trol population >1 was considered normal, T score between
1 and 2.4 was considered osteopenia, and T score 62.5
was considered osteoporosis [10].
Statistical analysis
Statistical presentation and analysis of the present study was
conducted, using the mean, standard deviation (t test), and
chi-square test by SPSS V.16.Table 5 Spearman’s rho rank correlations between T score
and pulmonary function tests in COPD group.
Parameters Correlation
coeﬃcient
p Value Sig.
Slow vital capacity (%) 0.07 >0.05 NS
Forced vital capacity (%) 0.562 <0.05 S
Forced expiratory volume
at ﬁrst second (%)
0.986 <0.001 HS
FEV1/FVC ratio 0.08 >0.05 NS
Forced expiratory ﬂow (25–75) 0.756 <0.001 HS
Peak expiratory ﬂow rate (%) 0.852 <0.001 HSResults
From Table 5 there was;
n Statistically highly signiﬁcant correlation between T score
and FEV1%, FEF (25–75)%, and PEFR%.
n Statistically signiﬁcant correlation between T score and
FVC%.
n Statistically non signiﬁcant correlation between T score and
SVC% and FEV1/FVC ratio.
Discussion
Osteoporosis continues to be a major problem in men with
chronic illness. In men with CLD, osteoporosis may be partic-
ularly disabling because vertebral fractures reduce vital capac-
ity, which further compromises ventilation [11]. Evidence
suggests that the prevalence of osteoporosis in patients with
COPD is high and potentially important [12,13].
In the present study, the COPD patients age ranged from 40
to 68 years (56.04 ± 7.14) and the age of the control group
ranged from 40 to 55 (49 ± 4.42) with no signiﬁcant difference
between the two groups as shown in (Table 1). But, the results
of body mass index showed signiﬁcant reduction in COPD
group in comparison with the control group as shown in (Ta-
ble 1). These results were in agreement with Iqbal et al. (2004)
who found signiﬁcant lower values of BMI in patients with
COPD than in normal personnel [14].
In this study, from 50 patients with different degrees of
COPD; 10 patients (20%) were normal as regards BMD, 27
patients (54%) were osteopenic as regards BMD and 13 pa-
tients (26%) were osteoporotic as regards BMD. While from
10 normal personnel; 8 (80%) were normal as regards BMD
and 2 (20%) were osteopenic as regards BMD.
Also it was demonstrated that 80% of patients with COPD
varying from moderate to very severe had abnormal BMD
either osteopenia (T score 1 to 2.4) which were 54%, or
osteoporosis (T score 62.5) which were 26% as shown in
(Table 2 and Fig. 1).
These results were in agreement with the results of the cross
sectional study carried by Jorgensen et al. (2007)on 62 COPD
patients who found that 78% of patients had low BMD either
osteopenic or osteoporotic [15].0 
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Figure 1 Comparison between COPD subgroups and control
group as regards number and percentage of normal, osteopenia
and osteoporosis.
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carried by Dubois et al. (2004) which carried on 86 patients with
COPDand revealed that; 28%of patients were normal as regards
BMD, 50% of patients were osteopenic as regards BMD, and
22% of patients were osteoporotic as regards BMD [16].
From the results of our study, it was demonstrated that
prevalence of osteopenia and osteoporosis increased with the
increasing in COPD degree from moderate to severe and then
very severe as shown in (Table 2 and Fig. 1). These results can
be explained as increase in COPD degree is associated with in-
crease of risk factors that lead to occurrence of osteoporosis
such as increased inﬂammatory load of COPD, using more
corticosteroid treatment, decrease in pulmonary functions,
and decrease in BMI.
These results were in agreement with the results of the study
carried by Sin et al. (2003), which revealed that risk of osteo-
penia increases by 30% in moderate COPD and by 70% in se-
vere COPD more than normal personnel, and the risk of
osteoporosis increases by 2.1 fold in moderate COPD and by
2.8 fold in severe COPD more than normal personnel [17].
In our work there was statistically high signiﬁcance between
the mean of T score of COPD group and the mean of T score
of control group that means BMD in COPD group was lower
than BMD in control group as shown in (Table 3).
These results were in agreement with the results of the study
carried by Lung Health Study Research Group (2000) which
carried on 412COPDpatients during duration of 3 years and re-
vealed that BMD was much lower in COPD patients than of
normal personnel of same sex and age [6]. These results alsowere
in agreement with the results of the study carried by McEvoy
et al. (2003) on 312 COPD patients and revealed low BMD in
COPD group more than in control group of the same sex and
age [18].
Table 4 shows that there is direct relation between FEV1%
and BMD in COPD patients who were osteoporotic.
These results were in agreement with Iqbal et al. (2004) who
found that, in COPD group who had osteoporosis BMD de-
creases in linear patren with the decrease of FEV1% [14]. Also,
these results were in agreement with the results of the cross sec-
tional study carried by Jorgensen et al. (2007) on 62 COPD pa-
tients who found that, BMD had direct relation with FEV1%
in COPD patients who had osteoporosis [15]. In contrast, Ves-
to et al. (2002) found that BMD in COPD patients had no rela-
tion with the degree of COPD, in other words there was no
relation between T score and FEV1% [19].
In the present study, by using spearman’s rho rank correla-
tion between T score and different spirometric parameters in
COPD group, there was; Statistically highly signiﬁcant correla-
tion between T score and FEV1%, FEF (25–75)%, and
PEFR%, statistically signiﬁcant correlation between T score
andFVC%, and statistically non signiﬁcant correlation between
T score and SVC%andFEV1/FVC ratio, as shown in (Table 5).
Incalzi et al. (2004) found that there were signiﬁcant corre-
lation between T score and all spirometric parameters except
FEV1% which had highly signiﬁcant correlation and SVC%
which had no signiﬁcant correlation [20].Conclusion
In conclusion, the present study showed that, osteoporosis is
highly prevalent in patients with moderate to very severeCOPD. Prevalence and severity of osteoporosis increased with
the increase of COPD degree.
Recommendations
On the basis of the ﬁnding in this study it is recommended that
all patients with COPD should be screened for osteoporosis in
order to initiate treatment for the disorder before they develop
fractures. Further studies are needed to determine the fre-
quency and severity of osteoporosis in mild COPD patients.References
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